The dates and venue for the upcoming Hematology event will be announced shortly.
For further details, Please contact us at secretary@magnusmeetings.com or call + 1 (702) 988 2320.
CHIP stands for clonal hematopoiesis of undetermined potential, which occurs when hematopoietic stem cells (HSCs) or other early blood cell progenitors contribute to the creation of a genetically unique subset of blood cells. This blood subpopulation is defined by a shared unique mutation in the cells' DNA, as the name implies; it is assumed that this subpopulation is "clonally" produced from a single founding cell and hence consists of genetic "clones" of the founder. When a stem or progenitor cell develops one or more somatic mutations that give it a competitive advantage in hematopoiesis over stem/progenitor cells without these mutations, a clonal population can form. Clonal hematopoiesis can also occur without a driving mutation, thanks to factors like neutral drift in the stem cell population. Clonal hematopoiesis can happen in healthy persons, but it's also been shown in patients with hematologic disorders. The size of the clonal population varies depending on the person; it can be as small as 2% of the blood or as much as 100%.
Gene therapy is a branch of medicine that focuses on genetically altering cells to provide a therapeutic effect or heal disease by repairing or reconstructing damaged genetic material. Gene therapy is based on the idea of correcting a genetic disease at its source. If, for example, a mutation in a gene results in the creation of a malfunctioning protein that causes a hereditary disease (typically recessively), gene therapy could be used to deliver a copy of the gene that does not include the detrimental mutation and thus creates a functional protein.
Title : Hereditary hemolytic anemias due to red blood cell membranopathies rheological and genetic approach
Joan Lluis Vives Corrons, Institute for Leukaemia Research Josep Carreras, Spain
Title : Histologic transformation of mantle zone lymphoma to diffuse large B-Cell lymphoma: A case report of disease relapse after Covid-19 infection
Lilija Bancevica, Riga Stradins University, Latvia
Title : Improving outcomes of curable lymphoma in resource constrained regions
Reena Nair, TATA Medical Centre, India
Title : Covid-19 and erythrocyte groups
Marina Nagervadze, Batumi Shota Rustaveli State University, Georgia
Title : Achieving 100% blood traceability compliance: A United Kingdom district hospital experience
Francis Ajeneye, Princess Alexandra Hospital NHS Trust, United Kingdom
Title : Role of erythrocytapheresis in sickle cell anemia crisis management: A tertiary care centre experience from Chhattisgarh state of central India
Neelesh Jain, Transfusion Medicine at Balco Medical Centre, India